Clinical trials: ALK Gene Translocation
Cancer, Cancer Metastatic
Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)
This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers.
- Conditions
- Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation
- Trial name
- TRacKING (NCT04921553)
- Testing
- Data collection and quality of life questionnaire
- Where
- 41 sites in Austria, Czechia and 9 more
- Volunteers
- 500 people
- Sponsor
- Centre Leon Berard
Lung Cancer, ALK Gene Mutation
Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients
Circulating tumor DNA can be used to monitor the treatment effect and identify developing resistance mutations during ALK directed TKI treatment.
- Conditions
- Lung Cancer, ALK Gene Mutation, Resistance, Disease, Mutation
- Trial name
- MonAlec (NCT04708639)
- Testing
- Alectinib
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Aarhus University Hospital
Non-small Cell Lung Cancer
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
This randomized, Phase III, multicenter, open-label study designed to evaluate the efficacy of Atezolizumab in combination with carboplatin, paclitaxel, bevacizumab compared with treatment with pemetrexed, cisplatin in…
- Trial name
- NCT03991403
- Testing
- Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab
- Where
- South Korea
- Volunteers
- 228 people
- Sponsor
- Samsung Medical Center
Anaplastic Lymphoma Kinase Gene Translocation, Non-Small Cell Lung Cancer
Immune and Genomic Markers in ALK+ NSCLC
The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)
- Trial name
- NCT04881916
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
ALK Gene Rearrangement, ALK Gene Translocation
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma…
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02201992
- Testing
- Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
- Where
- 1,618 sites in United States, Guam and 1 more
- Volunteers
- 166 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non Squamous Lung Cancer
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
- Trial name
- PROFILE 1014 (NCT01154140)
- Testing
- treatment
- Where
- 249 sites in United States, Australia and 29 more
- Volunteers
- 343 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
This was a Phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive non-small cell lung cancer.
- Trial name
- NCT02292550
- Testing
- Ribociclib, Ceritinib
- Where
- 8 sites in United States, France and 4 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Lung Adenocarcinoma Metastatic
A+C in Metastatic Lung Adenocarcinoma Cancer
This is a phase II, prospective, single arm, non comparative study with crizotinib combined with bevacizumab in treatment-naive lung adenocarcinoma cancer patients with ALK translocation or ROS1 translocation or MET amplification
- Trial name
- NCT02946359
- Testing
- Crizotinib, bevacizumab
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Carcinoma, Non-Small-Cell Lung
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene.
- Trial name
- NCT00932451
- Testing
- PF-02341066
- Where
- 280 sites in United States, Australia and 20 more
- Volunteers
- 1,069 people
- Sponsor
- Pfizer
Lung Cancer, Stage IIIb Lung Cancer
IPI-504 in NSCLC Patients With ALK Translocations
IPI-504 blocks a protein that is in cancer cells and is also in normal cells. This protein is called Heat Shock Protein-90 (Hsp90). Hsp90 helps protect certain other proteins from being destroyed by cells.
- Conditions
- Lung Cancer, Stage IIIb Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT01228435
- Testing
- IPI-504
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Drug Monitoring, Carcinoma, Non-Small-Cell Lung
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
The ADAPT ALEC randomized controlled trial (RCT) is performed in patients with Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC).
- Conditions
- Drug Monitoring, Carcinoma, Non-Small-Cell Lung, Lung Cancer, Anaplastic Lymphoma Kinase Gene Mutation
- Trial name
- ADAPT ALEC (NCT05525338)
- Testing
- Alectinib
- Where
- 8 sites in France, Netherlands
- Volunteers
- 196 people
- Sponsor
- University Medical Center Groningen
ALK Gene Translocation, EGFR Activating Mutation
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of plinabulin when given together with nivolumab and to see how well they work in treating patients with stage IIIB-IV non-small cell lung cancer that has come back or…
- Conditions
- ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation
- Trial name
- NCT02846792
- Testing
- Nivolumab, Plinabulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Non-Small Cell Lung Cancer
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
This is an open-label multi-center Phase 2 efficacy and safety study of crizotinib in East Asian patients with advanced Non-Squamous NSCLC harboring a translocation or inversion event involving the ALK gene locus who have…
- Trial name
- NCT01500824
- Testing
- Crizotinib
- Sponsor
- Pfizer
NSCLC (Non-small Cell Lung Cancer)
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
This is a Phase III, Randomized, Open-label, Efficacy and Safety Study of Crizotinib single agent versus Chemotherapy Regimens (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) in First-Line ALK (Anaplastic Lymphoma Kinase)…
- Trial name
- NCT01639001
- Testing
- Crizotinib, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin
- Where
- 47 sites in China, Hong Kong and 3 more
- Volunteers
- 207 people
- Sponsor
- Pfizer
Lung Cancer
Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
The purpose of this study is to try to learn more about how small molecule kinase inhibitor medications work in treating lung cancer.
- Trial name
- NCT01300429
- Testing
- obtain tissue specimens
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, NSCLC
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
This is an open-label, non-randomised, phase II, exploratory, multi-country and multi-centre clinical trial. Chemotherapy-naïve patients with EML4-ALK rearrangement and with locally advanced or metastatic non-small cell lung…
- Conditions
- Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV
- Trial name
- CUBIK (NCT04223596)
- Testing
- Brigatinib
- Where
- 15 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Fundación GECP
Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation
Lorlatinib Combinations in Lung Cancer
This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer.
- Conditions
- Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement, Relapsed Cancer
- Trial name
- NCT04292119
- Testing
- Lorlatinib, Crizotinib, Binimetinib
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Massachusetts General Hospital
Carcinoma, Non-Small-Cell Lung
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after…
- Trial name
- NCT00932893
- Testing
- PF-02341066, Pemetrexed, Docetaxel
- Where
- 264 sites in United States, Australia and 20 more
- Volunteers
- 347 people
- Sponsor
- Pfizer
Mediastinal Lymphadenopathy, Hilar Lymphadenopathy
Endobronchial Ultrasound Needle Aspiration With and Without Suction
The main purpose of the present study is to compare the diagnostic yield of different aspiration techniques in Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) in the diagnosis of hilar/mediastinal adenopathy
- Conditions
- Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma, Lung Neoplasms
- Trial name
- NCT05110950
- Testing
- No suction EBUS-TBNA, Passive suction through dedicated EBUS-TBNA syringe, Manual applied suction EBUS-TBNA through a pistol-grip syringe holder
- Where
- Italy
- Volunteers
- 306 people
- Sponsor
- Università Politecnica delle Marche